ABSTRACT
Many popular disease transmission models have helped nations respond to the COVID-19 pandemic by informing decisions about pandemic planning, resource allocation, implementation of social distancing measures and other non-pharmaceutical interventions. We study how five epidemiological models forecast and assess the course of the pandemic in India: a baseline model, an extended SIR (eSIR) model, two extended SEIR (SAPHIRE and SEIR-fansy) models, and a semi-mechanistic Bayesian hierarchical model (ICM). Using COVID-19 data for India from March 15 to June 18 to train the models, we generate predictions from each of the five models from June 19 to July 18. To compare prediction accuracy with respect to reported cumulative and active case counts and cumulative death counts, we compute the symmetric mean absolute prediction error (SMAPE) for each of the five models. For active case counts, SMAPE values are 0.72 (SEIR-fansy) and 33.83 (eSIR). For cumulative case counts, SMAPE values are 1.76 (baseline) 23.10 (eSIR), 2.07 (SAPHIRE) and 3.20 (SEIR-fansy). For cumulative death counts, the SMAPE values are 7.13 (SEIR-fansy) and 26.30 (eSIR). For cumulative cases and deaths, we compute Pearson’s and Lin’s correlation coefficients to investigate how well the projected and observed reported COVID-counts agree. Three models (SAPHIRE, SEIR-fansy and ICM) return total (sum of reported and unreported) counts as well. We compute underreporting factors as of June 30 and note that the SEIR-fansy model reports the highest underreporting factor for active cases (6.10) and cumulative deaths (3.62), while the SAPHIRE model reports the highest underreporting factor for cumulative cases (27.79).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors would like to thank the Center for Precision Health Data Sciences at the University of Michigan School of Public Health, The University of Michigan Rogel Cancer Center and the Michigan Institute of Data Science for internal funding that supported this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
References were missing. Has been added.
Data Availability
All data and code available at covind19.org
